Navigation Links
Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
Date:4/2/2009

NEW HAVEN, Conn., April 2 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that its lead compound, delafloxacin, has been selected by R&D Directions editors for the 8th annual report on "100 Great Investigational Drugs," published in the March 2009 issue.

R&D Directions is a leading pharmaceutical industry magazine. Compounds selected by editors for the report, including delafloxacin, demonstrated "particular promise in a... growing therapeutic area of unmet medical need... and target disease pathways using a distinctly innovative mechanism of action."(1)

"We are honored to have our lead compound, delafloxacin, recognized by the editors of R&D Directions as one of the top 100 investigational drugs of 2009," said Susan Froshauer, PhD, President and CEO of Rib-X Pharmaceuticals. "The broad spectrum activity demonstrated by delafloxacin against a wide range of highly-resistant bacteria may offer the medical community a much needed treatment alternative for a variety of serious hospital treated infections, including complicated skin, hospital acquired pneumonia, endocarditis and others. We are proud of the work we have done at Rib-X to further the development of this compound."

A copy of the R&D Directions 100 Great Investigational Drugs of 2009 report can be viewed at http://www.rddirections.com/magazines/randd/.

About Delafloxacin

Delafloxacin, a novel, broad spectrum, next-generation fluoroquinolone, has demonstrated better activity than other quinolones against Gram-positive bacteria, including isolates of MRSA that are re
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
2. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
3. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
4. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
5. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
6. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
7. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
8. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
9. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
10. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
11. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... WASHINGTON, Dec. 6, 2011  BodyMedia, the leading developer ... Qualcomm Life, a wholly owned subsidiary of Qualcomm ... BodyMedia FIT ™ LINK Armband ... BodyMedia Armband users to share wireless health data, ...
... 6, 2011  Echo Therapeutics, Inc. (Nasdaq: ECTE ... a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system ... today announced a registered direct equity financing of approximately ... of one share of its common stock and a ...
Cached Medicine Technology:BodyMedia Plans to Join Qualcomm Life's Wireless Health 2net Ecosystem 2BodyMedia Plans to Join Qualcomm Life's Wireless Health 2net Ecosystem 3BodyMedia Plans to Join Qualcomm Life's Wireless Health 2net Ecosystem 4Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing 2Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing 3
(Date:7/9/2014)... may smell of flatulence and have a reputation for being ... hydrogen sulfide is now being being found to offer potential ... stroke, heart attacks and dementia. A new compound (AP39), designed ... key to future therapies, by targeting delivery of very small ... inside cells. , Scientists in Exeter have already found ...
(Date:7/9/2014)... most important organs in the human body. Its job ... this is its synthesis function and that ... is its detoxification function. Lack of exercise and too ... liver. The resulting diseased cells can lead to inflammations, ... According to the German Liver Foundation, over five million ...
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
(Date:7/9/2014)... , , , , ... , , , , ... rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , , , ... , , , , , , , ...
(Date:7/9/2014)... diseases has risen dramatically in Western societies. One frequently ... microorganisms and have fewer infections than previous generations, thereby ... by researchers at Sahlgrenska Academy, University of Gothenburg, monitored ... of the immune system in relation to allergic disease. ... the Vstra Gtaland Region, half of them on farms ...
Breaking Medicine News(10 mins):Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... SATURDAY, Oct. 1 (HealthDay News) -- Halloween candy may ... unexpected allergy and asthma triggers that can pose a ... makeup, according to experts from the American College of ... of Halloween-associated allergies, they focus on candy and often ...
... 30, 2011Young adults undergoing addiction treatment arrive ready and ... recovery, but it,s the help and guidance received during ... a longitudinal study published electronically and in press within ... study was conducted collaboratively by the Center for Addiction ...
... late nineties, researchers from a promising yet volatile French ... their own horse. The seven founders teamed-up with ... industry and with Gemmes Ventures, an investment fund specialising ... names such as Rotschild are backing CrossJect, which is ...
... Ph.D., vice president of research for Lifespan ( www.lifespan.org ), ... the annual ceremony last night at Harvard University. Snyder, along ... and Yale Medical School, were recognized for their work which ... have the same impact on impairing cognitive function as small ...
... A program designed to accelerate the entry of ... following completion of their graduate research degree or ... National Institutes of Health Director,s Early Independence Awards ... empower the biomedical research workforce, particularly through the ...
... Men over 75 with prostate cancer who are otherwise healthy ... study. Meanwhile, younger men with prostate cancer who ... -- are being treated for their cancer, but not responding ... researchers found. "This study suggests that men with certain ...
Cached Medicine News:Health News:Halloween Trappings Can Trigger Asthma, Allergies 2Health News:Study shows young adults want to recover from addiction but need help to make it happen 2Health News:An innovation star for Europe 2Health News:An innovation star for Europe 3Health News:Lifespan researcher wins Ig Nobel Prize 2Health News:NIH program allows junior investigators to bypass traditional post-doc training 2Health News:Otherwise Healthy Older Men Undertreated for Prostate Cancer: Study 2Health News:Otherwise Healthy Older Men Undertreated for Prostate Cancer: Study 3
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Rapid latex slide agglutination assay for the qualitative and semi-quantitative determination of Rheumatoid Factors in human serum....
Medicine Products: